BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program https://t.co/VwzI9aInGl https://t.co/s2elEE7Qb0
Nice @AlumkalJoshi great to see this out
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program https://t.co/5ja5ZMActf
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program https://t.co/wJSJuiU9Vu
RT @NatRevUrol: A study in @CCR_AACR reports that E2F1& BRD4 are critical for activating an AR-repressed, t-NEPC lineage plasticity program…
A study in @CCR_AACR reports that E2F1& BRD4 are critical for activating an AR-repressed, t-NEPC lineage plasticity programme in PCa and that BET inhibition is a promising therapeutic approach https://t.co/3exJyGJKpt
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program https://t.co/3CwUBUxXMB
RT @CR_AACR: Read the article: https://t.co/aeOeOc4hQO https://t.co/HF62eBBbBH
Read the article: https://t.co/aeOeOc4hQO
New article: BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program https://t.co/JwSf2ngSy4 #prostatecancer #oncology https://t.co/JSdJhtGUDH
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program https://t.co/2LEH00DDXF
Read the study in @CCR_AACR: https://t.co/dS4y0RkoSW